Our product pipeline consists of potentially first-in-class and best-in-class drug candidates for the treatment of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
XW003
(Ecnoglutide Injection)
Ecnoglutide is a novel cAMP signaling biased, long-acting GLP-1 analog optimized for improved biological activity, stability and scalability. It is the first-in-class to successfully complete phase III clinical trials in support of Marketing Authorization Applications in China for the treatment of type 2 diabetes and obesity. Part of the phase III results have been presented at the Scientific Sessions of the American Diabetes Association and the European Association for the Study of Diabetes, confirming the robust and sustainable efficacy in the treatment of type 2 diabetes and obesity, as well as the favorable safety and tolerability.
XW004
(Oral Ecnoglutide)
XW004 is a phase II ready, oral formulation of Ecnoglutide, that has demonstrated best-in-class efficacy potential in a phase I clinical trial in Australia, which also confirmed the viability of once-weekly dosing.
XW014
(Oral small molecule GLP-1RA)
(Amylin Injection)
XW014 is an orally bioavailable, small molecule GLP-1RA, in phase I clinical development in US for the treatment of type 2 diabetes and obesity. Compared with GLP-1 peptides, a small molecule compound is easier to manufacture and formulate for oral dosing. Additionally, XW014 has the potential to be co-formulated with other oral administration drugs of complementary mechanisms to generate more effective combination therapies that could also improve treatment adherence.
XW015
XW015 is a novel, long-acting amylin analog in IND-enabling studies. It is optimized for increased biological activity and stability for use as monotherapy or in combination with GLP-1 peptide that can deliver improved efficacy for treating obesity, type 2 diabetes and MASH.
XW016
(Oral Amylin)
XW016 is a potential first-in-class, once-weekly oral amylin analog in IND-enabling studies. It is optimized for use as monotherapy or in combination with an oral GLP-1 agonist that can offer improved efficacy as well as patient-friendly dosing.